Evaluation of the impact of everolimus on cognitive function in an animal behavioural model.
Coordinator: Castel, H
Background: Some cancer patients treated with everolimus, an mTOR pathway inhibitor, experience fatigue or anorexia. Therefore, it is important to research the specific role played by this molecule during cancer treatment and investigate the link between fatigue and cognitive function in an animal model.
Objectives: The objective of this research was therefore to assess the impact of a targeted therapy, everolimus, on cognitive function and cytochrome oxidase activity (neuronal activity) in a young mouse model.
Study methodology: Behavioural tests in C57B/L6 mice and neurobiological analyses on brain samples. Administration of targeted therapy by gavage.
Current study status: closed
Collaboration: PsyNCA and F. Baclesse
Sponsor: Novartis, Inserm and TC2N
Dubois M, Le Joncour V, Tonon MC, Anouar Y, Proust F, Morin F, Gandolfo P, Joly F, Hilber P, Castel H. Evaluation of the impact of the cancer therapy everolimus on the central nervous system in mice. PLoS One. 2014 Dec 1;9(12):e113533.